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Abstract
Background: Serum concentrations of soluble urokinase-type plasminogen activator receptor (suPAR)
have a strong independent association with HIV-1-related mortality. The practical utility of plasma suPAR
in assessing short-term all-cause mortality risk was evaluated in patients with advanced immunodeficiency
enrolling in an antiretroviral treatment (ART) programme in South Africa.
Methods: An enzyme-linked immunosorbent assay (ELISA) was used to measure plasma concentrations
of suPAR in patients at the time of enrolment to the ART programme. The association between plasma
suPAR concentrations, baseline patient characteristics and cohort outcomes after 4 months of ART were
determined.
Results: Patients (n = 293, 70% female) had a median age of 33 years and were followed up for a median
of 5 months from enrolment. The median CD4 cell count was 47 cells/µl (IQR = 22–72) and 38% of
patients had WHO stage 4 disease. 218 (74%) patients remained alive after 4 months of ART; 39 (13%)
died and 36 (12%) were lost to the programme for other reasons. Patients who died had significantly higher
plasma suPAR concentrations compared to those who either survived (P < 0.01) or left the programme
for other reasons (P < 0.043). In multivariate analysis, higher log10 suPAR concentrations were significantly
associated with lower CD4 cell counts, WHO clinical stage 4 disease and male sex. In multivariate analysis
to identify factors associated with death, log10 suPAR concentration was the most strongly associated
variable (P < 0.001). However, examination of sensitivity and specificity characteristics using receiver
operating characteristic (ROC) analysis revealed that results from this assay did not have a discriminatory
cut-point to provide clinically useful information.
Conclusion: Plasma suPAR concentration was the strongest independent predictor of short-term
mortality risk among patients with advanced immunodeficiency enrolling in this ART programme.
However, lack of a discriminatory threshold did not permit this marker to be used to triage patients
according to short-term mortality risk.
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Background
In 2005 an estimated 25.8 million adults and children in
sub-Saharan Africa were living with HIV/AIDS; 4.7 mil-
lion were in immediate need of antiretroviral treatment
(ART) and 2.4 million died [1,2]. Access to ART in the
region is expanding and is estimated to have averted
250,000–350,000 deaths in low- and middle-income
countries in 2005 alone [3]. Early pessimism that ART
could not be effectively delivered on a large scale using a
simplified public health approach has largely proven
unfounded, at least in the short term. ART access has been
rapidly expanded on a massive scale in Lusaka, Zambia,
for example, and on a country-wide scale in Malawi with
generally good early clinical outcomes [4,5]. However, an
important issue to emerge in ART programmes in
resource-limited settings is that, following initiation of
ART, early mortality is very high [6].
In cohorts in sub-Saharan Africa, on-treatment mortality
during the first 12 months of ART ranges between 7% and
26% and predominantly occurs within the initial months
of ART [4,7-11]. A report from a South African cohort also
found that mortality occurring in the one month period
while patients were preparing for ART accounted for 67%
of early in-programme deaths [7]. This suggests that even
short delays in starting ART may be associated with con-
siderable mortality risk. Mortality is also likely to accrue as
a result of delays within the health system upstream of
ART programmes [12]. Additional delays may arise due to
the practical constraints imposed by the sheer numbers of
patients seeking to start treatment in some settings and
this may require some form of patient prioritisation.
Delays in starting ART must be minimised for those at
high risk of death. Identification of a simple laboratory
assay that provides prognostic information beyond that
provided by blood CD4 cell count might provide a means
of identifying those at highest mortality risk. Such a triage
tool might facilitate prioritisation of patients, permitting
more rapid initiation of ART and higher intensity medical
follow-up in those at greatest risk of death. Low blood
haemoglobin and increased serum concentration of B2-
microglobulin, for example, are each independently asso-
ciated with mortality [4,10,13]. However, the additional
prognostic value of these parameters is somewhat limited.
The plasma concentration of soluble urokinase-type plas-
minogen activator receptor (suPAR, CD87) is a strong
independent predictor of mortality in untreated patients
with HIV-1 infection [14,15] and levels decrease in paral-
lel with the response to ART [16]. Plasma concentrations
of this immune marker can be quickly and inexpensively
measured using a simple enzyme-linked immunosorbent
assay (ELISA), which requires much less sophisticated lab-
oratory infrastructure than that needed for CD4 cell count
or plasma viral load measurement. Such an assay might
therefore be potentially useful in resource-limited set-
tings, especially as the assay could potentially be further
simplified to a clinic-based point of care test and could
use urine rather than serum [17]. The practical utility of
measurements of this immune marker, however, has not
been adequately evaluated within clinical HIV services.
We have previously described a community-based ART
programme in Cape Town, South Africa, in which mortal-
ity rates, risk factors and causes have been reported in
detail [7,11,18,19]. In this study we examined the prog-
nostic utility of plasma suPAR concentrations among
HIV-infected patients with advanced immunodeficiency
and high risk of mortality.
Methods
Antiretroviral treatment programme
The ART service based at the Gugulethu Community
Health Centre, in Cape Town, South Africa has previously
been described [20-22]. The district it serves has a pre-
dominantly African population of over 300,000, the vast
majority of whom live in conditions of low socioeco-
nomic status. In 2003 the antenatal HIV seroprevalence
was 28%. Patients are referred from primary care HIV clin-
ics in the community to the ART programme. Treatment
criteria are based on the WHO 2002 recommendations
[23], which include those with a prior AIDS diagnosis
(WHO stage 4 disease) or a blood CD4 cell count <200
cells/µl.
The mean time between enrolment of a patient in the serv-
ice and initiation of ART is approximately one month,
permitting thorough evaluation of patients (including
screening for tuberculosis) and preparation for treatment
as described previously [7,11,20,21]. Blood samples are
routinely drawn on all patients at a standard clinic visit
during this period to measure CD4 cell counts by flow
cytometry (FACSCount™, Becton Dickinson, Franklin
Lakes, NJ, USA) and plasma viral load using Versant™
HIV-1 RNA 3.0 branched chain DNA assay (Bayer Health-
Care, Leverkusen, Germany). Excess EDTA plasma is
stored at ≤ -80°C.
First-line ART, comprised of stavudine, lamivudine plus a
non-nucleoside reverse transcriptase inhibitor (efavirenz
or nevirapine), was supplied free of charge. Treatment
adherence and viral load suppression <400 copies/ml in
this cohort both exceed 90% at all 16 weekly follow-up
time-points [20]. All patients with CD4 counts <200 cells/
µl received prophylaxis with daily cotrimoxazole or dap-
sone as an alternative but isoniazid prophylaxis was not
used. In addition to scheduled clinic appointments at 4, 8,
and 16 weeks and 16-weekly thereafter, patients had open
access to the clinic for medical problems.
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Assignment of each patient to a community-based thera-
peutic counsellor promotes high levels of treatment com-
pliance and also high levels of data-completeness so that
final outcomes are known for the vast majority of
patients. A proportion of patients did not initiate treat-
ment for a variety of reasons other than death and such
individuals were deferred from the programme and fol-
low-up was censored at the time they exited the pro-
gramme. Principal causes of death in this cohort have
been previously been described in detail and include
wasting syndrome, acute sepsis, tuberculosis, malignancy
and immune reconstitution disease (mainly associated
with cryptococcal meningitis) [7,19,24].
Structured clinical records were maintained on all patients
screened on entry to the ART programme and this infor-
mation was transferred on a weekly basis to a computer
database. All patients enrolling in studies at this ART clinic
provide written informed consent and this study was
approved by the Research Ethics Committee of the Uni-
versity of Cape Town.
Plasma suPAR concentrations
Total plasma suPAR concentrations were measured at a
single time-point in plasma samples that had been stored
at the time of programme enrolment. In order to assess
this prognostic marker a patient population with high
mortality risk, we selected all patients who enrolled into
the programme between September 2002 and February
2005 and who had a CD4 cell count ≤100 cells/µl.
Plasma suPAR concentrations were measured using a
commercially available enzyme-linked immunosorbent
assay (ELISA) (suPARnostic,™ ViroGates, Lyngby, Den-
mark) following the manufacturer's instructions. This is a
simple double monoclonal antibody sandwich assay that
measures total suPAR, including both full-length and
cleaved forms of the receptor. In brief, a standard control
curve (range 0.6 – 19.3 ng/ml), positive control, and test
samples were incubated in duplicates in a 96-well plate
pre-coated with anti-suPAR antibody. Following further
incubation with a secondary peroxidase-conjugated anti-
body, the assay was developed by addition of a tetrameth-
ylbenzidine (TMB) chromogenic substrate. The reaction
was terminated by addition of sulphuric acid and absorb-
ance at 450 nm was determined using a microtitre plate
reader. The linear standard curve was used to determine
concentrations in positive control and test samples. Sam-
ples with concentrations exceeding the highest standard
(19.3 ng/ml) were reanalysed using a further 5-fold sam-
ple dilution.
Data analysis
Outcomes for all patients were determined from the time
of entry to the programme until completion of 4 months
ART or exit from the programme due to death or other
causes. Data were analysed using STATA Version 9.0 (Col-
lege Station, Texas, USA) and GraphPad Prism 4.0
(GraphPad Software Inc. San Diego, CA, USA). As the fre-
quency distribution of values was highly right-skewed, the
suPaR values were log10-transformed for bivariate analy-
ses (based on the Mann Whitney U or Kruskall Wallis tests
to compare medians) and multivariate modelling. We
constructed multiple linear regression models to predict
suPAR values at programme enrolment, and used Cox's
proportional hazards to examine the associations
between suPAR concentrations and the relative hazard of
mortality. For the latter set of models, time at risk was cal-
culated from entry into the programme to the first of
death, transfer out of the programme, loss to-follow-up,
or the 4 month follow-up visit on ART. Receiver operating
characteristic (ROC) curves were constructed to examine
the effect of different cut-points of log10 suPAR values on
the sensitivity and specificity of predicting mortality dur-
ing the study period. Confidence intervals for the area
under the ROC curves were calculated using the method
described by Bamber [25].
Results
Patient baseline characteristics and follow-up
Of patients who enrolled into the ART programme
between September 2002 and February 2005, 354 had a
blood CD4 cell count ≤100 cells/µl. Of these, a stored
plasma sample was available for measurement of suPAR
concentration in 293 (83%) patients and these were
included in the study. These patients had a median age of
33 years and approximately two-thirds were female (Table
1). 89% had either WHO stage 3 or 4 disease. A total of
43% of patients had either an active diagnosis of TB prior
Table 1: Patient characteristics (n = 293)
Age median (IQR), years 33(29–38)
Female sex 205(70)
Median (IQR) CD4 cell count 47(22–72)
WHO Stage
1/2 32(11)
3 150(51)
4 111(38)
Viral load > 105 copies/ml 149(51)
Tuberculosis,
Present at enrolment 80(27)
Developed during ART 47(16)
Median (IQR) duration
follow up (days) 145(139–173)
Outcome
Alive on ART 218(74)
Deaths pre or during ART 39(13)
Non-death losses 36(12)
Baseline characteristics and outcome of patients enrolling in the 
antiretroviral treatment (ART) programme who were included in the 
analysis. Unless otherwise stated, values are numbers (%) of patients.
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to initiation of ART or developed symptoms during the
first 4 months of ART that were due to confirmed incident
TB.
Twenty-four (8%) patients did not start ART due to death
before starting treatment (n = 13) or other reasons (n =
11), including treatment refusal, loss to follow-up or
access to treatment at another clinic. A total of 269 (92%)
patients did start ART. Of these, 218 (82%) were retained
within the programme and were alive after 16 weeks of
treatment. Twenty six (9.7%) patients died within the first
16 weeks of treatment. Other programme losses during
ART included 15 (5.6%) patients who moved out of area
and 10 (3.7%) who were lost to follow-up. The median
(IQR) total period of follow-up was 145 days (139–173)
and was comprised of a median pre-ART period of 34 days
(28–56) and a median of 112 days (112–119) on ART.
Plasma suPAR concentrations
Detectable levels of suPAR were measured in plasma sam-
ples from all 293 patients. The standard curves for each
run were linear (mean r2 = 0.995; SD = 0.004) and all pos-
itive control readings were consistent with the expected
value. The median suPAR concentration in the patient
plasma samples was 4.05 ng/ml (IQR, 3.03–5.77; range
1.14–52.4 ng/ml) or 0.607 log10 ng/ml (IQR = 0.481–
0.761).
Associations between baseline patient characteristics and
log10 suPAR concentrations were examined (Table 2). In
unadjusted analyses, low baseline CD4 cell counts and
WHO stage 4 disease were strongly associated with higher
log10 plasma concentrations of suPAR. There was also a
trend towards patients with active TB diagnoses having
higher suPAR concentrations. When the cases of tubercu-
losis were subdivided into those with active TB at the time
of the blood sample and those who developed later tuber-
culosis during ART, neither group was significantly associ-
ated with suPAR concentration. Other baseline
characteristics, however, were not significantly associated
with suPAR concentrations. In adjusted analyses, the asso-
ciation with CD4 cell count and WHO stage remained,
but female sex was also found to be significantly associ-
ated with lower suPAR concentrations (Table 2).
Patient outcomes and suPAR concentrations
To examine the association between log10 serum suPAR
concentrations and clinical outcome, patients were
divided into three groups according to final outcome: (i)
received ART and alive after 4 months treatment (n = 218,
74%); (ii) died during the analysis period (n = 39, 13%);
or (iii) other programme losses (n = 36, 12%). Among
those who died, 13 died before starting ART and 26 died
during the first 4 months of ART.
The median log suPAR concentration among patients who
died (0.761 ng/ml, IQR = 0.548–0.949 ng/ml) was signif-
icantly greater than that of patients who remained alive on
ART (median = 0.583 ng/ml, IQR = 0.479–0.715 ng/ml)
or who were lost to the programme for reasons other than
death (median = 0.609 ng/ml ng/ml; IQR = 0.429–0.833
ng/ml) (Figure 1). However, concentrations did not differ
significantly comparing those who remained alive with
non-death losses. Thus, higher suPAR concentrations were
strongly associated with mortality. However, median
suPAR concentrations were almost identical comparing
those who died pre-ART with those who died during the
first 4 months of ART (5.92 and 5.93 ng/ml, respectively)
and suPAR concentrations were not associated with causes
of death (data not shown).
Table 2: 
Patient characteristic Unadjusted association Adjusted association
Mean change log suPAR per unit 
increase in variable
95% CI P value Mean change log suPAR per unit 
increase in variable
95%CI P value
Age (years) -0,0001 -0.0038,
0.0035
0.944 0.0018 -0.0020,
0.0056
0.353
Female -0.0362 -0.0950,
0.0226
0.227 -0.0615 -0.1228,
-0.0002
0.049
CD4 cell count (cells/µl) -0.0014 -0.0026,
-0.0005
0.003 -0.0012 -0.0022,
-0.0029
0.011
Log10 viral load (copies/ml) 0.0328 -0.0149,
0.0806
0.177 0.0219 -0.0253,
0.0691
0.361
WHO stage 1,2,3 versus 4 0.0691 0.0140,
0.1243
0.014 0.0566 -0.0003,
0.1136
0.051
Tuberculosis (all cases) 0.0482 -0.0087,
0.1051
0.097 0.0380 -0.0187,
0.0947
0.189
Crude associations between baseline patient characteristics and log10 plasma suPAR concentrations (ng/ml) measured at baseline.
BMC Infectious Diseases 2007, 7:41 http://www.biomedcentral.com/1471-2334/7/41
Page 5 of 8
(page number not for citation purposes)
Predictors of mortality
We next examined predictors of mortality using multivar-
iate analysis. In an initial model that included baseline
patient characteristics but excluded suPAR concentration,
only baseline CD4 cell count was significantly associated
with mortality. There was also a strong trend towards an
association with WHO clinical stage (Table 3a). However,
when the log concentration of plasma suPAR was
included in the model, the strength of the associations
with CD4 cell count and WHO stage were diminished and
log suPAR concentration was found to be the strongest
independent predictor of mortality (Table 3).
Having demonstrated that plasma suPAR concentration
was strongly associated with mortality at a group level, we
next examined the utility of this as a prognostic test to be
applied to individual patients. To do this, receiver operat-
ing characteristic (ROC) curve analysis was done (Figure
2). The area under the ROC curve was moderate (0.681;
95% CI 0.582–0.781) and yet a clear cut-point that max-
imised the ability of suPAR concentration to distinguish
between patients who died or survived was lacking. Using
cut-points of ≥5.0 ng/ml, ≥10.0 ng/ml or ≥15 ng/ml, the
corresponding sensitivity and specificity values showed
that none of these cut-offs provided sufficient sensitivity
and specificity that would be clinically useful in this
patient population (Figure 2).
Discussion
In this study we examined the utility of plasma suPAR
concentrations for predicting all-cause mortality among
HIV-infected patients with advanced immunodeficiency
early in an ART programme in South Africa. Our observa-
tions add to previous findings from Europe that plasma
suPAR is an independent predictor of mortality in
untreated cohorts of HIV-infected persons [14,15]. We
also found that mortality was more strongly associated
with suPAR concentration than with any other risk factor
including CD4 cell count and WHO clinical stage. How-
ever, despite these strong associations, there was no useful
cut-point in the distribution of suPAR concentrations that
could discriminate adequately between groups with
higher and lower mortality risk. Thus, the marker was
unable to serve as a useful adjunctive tool to assess short-
term mortality risk in this patient population.
SuPAR is a component of the plasminogen activation sys-
tem, which comprises urokinase-type plasminogen activa-
tor (uPA) and its receptor (uPAR) [26]. uPAR is expressed
on a variety of different immune cells and vascular
endothelial cells. It is involved in the recruitment of leu-
kocytes from the circulation to extravascular sites of
inflammation through regulatory effects on pericellular
proteolysis, cell adhesion, chemotaxis, and signal trans-
duction [26,27]. suPAR is generated by either proteolytic
cleavage or shedding from cells. Serum concentrations are
increased and prognostic in a variety of inflammatory and
Table 3: 
Characteristic (a) Hazard ratio 95% CI P value (b) Hazard ratio 95% CI P value
Age 1.00 0.96–1.05 0.844 1.00 0.96–1.04 0.985
Male 1.30 0.65–2.60 0.464 1.68 0.84–3.39 0.142
Baseline CD4 cell count 0.99 0.97–1.00 0.028 0.99 0.98–1.00 0.059
Log10 Viral load (copies/ml) 0.94 0.50–1.78 0.848 0.85 0.45–1.61 0.612
WHO stage 4 1.91 0.98–3.73 0.059 1.62 0.83–3.16 0.162
Tuberculosis (all cases) 1.13 0.59–2.17 0.710 0.95 0.49–1.86 0.883
Log suPAR concentration ng/ml - - - 9.96 2.78–35.7 <0.001
Cox proportional hazards model showing the association between baseline characteristics of patients (n = 293) and subsequent death before 
starting antiretroviral treatment (ART) or during the first 16 weeks ART. The first model (a) shows associations with baseline patient 
characteristics whereas the second model (b) also includes plasma log suPAR concentration.
Log10 suPAR concentrations among patients (n = 293) enroll-ing in an antiretroviral treatment (ART) programmeFi ure 1
Log10 suPAR concentrations among patients (n = 293) enroll-
ing in an antiretroviral treatment (ART) programme. Individ-
ual data points represent individual patients who were either 
receiving ART and alive after completing 4 months of treat-
ment (n = 218), had died before starting ART or during the 
first 16 weeks of treatment (n = 39), or were lost to the pro-
gramme (n = 36). Group median values are shown by a bar.
Alive on ART Deaths Other losses
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
L
o
g
 s
u
P
A
R
c
o
n
c
.
2.00 P<0.001 P=0.043
P=0.595
BMC Infectious Diseases 2007, 7:41 http://www.biomedcentral.com/1471-2334/7/41
Page 6 of 8
(page number not for citation purposes)
neoplastic disease states, including HIV infection, tuber-
culosis, sepsis, rheumatoid arthritis and certain malignan-
cies and suPAR concentrations reflect prognosis in these
disease states [14,15,17,28-30].
In European cohorts of HIV-infected patients plasma
suPAR concentrations were higher among those with
more advanced clinical stages of disease [14,15]. This is
likely to reflect the fact that systemic immune activation
increases with HIV disease progression and is central to
the pathogenesis of the infection [31]. In this study we
also found that higher suPAR concentrations were signifi-
cantly associated with advanced WHO stage of disease
and lower blood CD4 cell counts. Absolute levels reported
in this patient population are consistent with those found
in previous studies [14,15]. High suPAR concentrations
were also found to be weakly associated with male sex.
This has not previously been reported although it is inter-
esting that male sex was an independent risk factor for
early mortality in several African ART cohorts [4,11,32].
Although tuberculosis has been found to be associated
with increased supAR levels [28] there was no such associ-
ation in this study. This may reflect the fact that those who
were free of tuberculosis may have had a high frequency
of other opportunistic infections, which also increase
suPAR concentrations, thereby masking any association
with TB.
The association between high suPAR concentrations and
mortality was highly statistically significant both at a
group level (Figure 1) and in multivariate analysis (Table
3). However, the distributions of suPAR concentrations in
those who survived and those who died were very broadly
overlapping (Figure 1). This is likely to reflect the fact that
suPAR is a non-specific inflammatory marker with a con-
tinuous distribution. As a result, using ROC analysis it was
not possible to identify a useful cut-point that provided
adequate sensitivity and specificity to enable the assay to
be used to discriminate those at highest risk of death. This
assay could therefore not be used to triage patients accord-
ing to mortality risk as they enrolled into this ART pro-
gramme.
A strength of this study is that we studied patients in a
community-based service that is likely to be representative
of other public sector ART clinics elsewhere in sub-Saha-
ran Africa. Moreover, a cohort rather than case control
design reduced potential for patient selection bias. Com-
pleteness of outcome data in this cohort was high due to
active community-based follow-up of patients using peer
counsellors. Some patients who were lost to the pro-
gramme for reasons other than death may have subse-
quently died. However, these patients were categorised
separately in the group analysis and their median suPAR
concentration did not differ from that of the group who
remained alive. Previous studies have only examined
associations between plasma suPAR concentrations and
prognosis in HIV-infected patients at a group level. This is
the first study to evaluate the practical clinical utility of
this marker in a clinical setting.
The study assessed short-term mortality risk over a
median of 5 months from enrolment. An important rea-
son for this is that we have previously reported that deaths
in this period are strongly associated with baseline
patients characteristics [11] whereas deaths occurring
beyond this period are only associated with response to
ART. Previous studies of the prognostic value of suPAR
concentration have reported on much longer durations of
follow-up of 3 years [15] and 5 years [14] in natural his-
tory cohorts. Plasma suPAR concentrations may have
greater prognostic value in assessing long-term mortality
risk when assessed in patients with less advanced immun-
odeficiency. However, short-term mortality risk is of great-
est relevance to clinicians making clinical decisions and
for developing treatment guidelines [33,34].
Only patients with advanced immunodeficiency were
included and the restricted cohort composition may have
diminished the association between mortality and risk
Receiver operating characteristic (ROC) curve analysis showing the util ty of plasma suPA  concentration a  a prog-nostic test redicting de th up to the first 4 months of ARTFigure 2
Receiver operating characteristic (ROC) curve analysis 
showing the utility of plasma suPAR concentration as a prog-
nostic test predicting death up to the first 4 months of ART. 
The area under the curve is 0.681.
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factors such as CD4 cell count. This would also explain the
lack of association with plasma viral load [35]. Despite
the cohort composition, the association between mortal-
ity and plasma suPAR concentrations was nevertheless
very strong at a group level. The data from this study are
relevant to patients with advanced disease who are already
eligible for ART and cannot be generalised to those with
earlier disease. Whether this assay can provide useful
prognostic information relevant to when ART should be
started needs to be assessed in future studies. This will
depend on whether the distribution of suPAR concentra-
tions in patients with earlier stages of disease has a dis-
criminatory threshold.
In conclusion, at a group level plasma suPAR concentra-
tions are strongly predictive of mortality among HIV-
infected patients in sub-Saharan Africa, confirming the
findings of previous studies in Europe. However, the lack
of a cut-point that provides adequate sensitivity and spe-
cificity to predict mortality in this patient population pre-
vented this assay from providing clinically useful
prognostic information for individual patient manage-
ment.
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